Pfizer is reportedly seeking approval for a 4th dose of COVID-19 vaccines for seniors
Pfizer is expected to seek authorization for a fourth dose in its COVID-19 vaccine regimen for seniors, The Associated Press reported Tuesday.
The additional booster shot would go to Americans 65 and older, in an effort to provide additional protection to age groups that are more vulnerable to serious illness by the coronavirus.
Pfizer has not yet submitted its request to the Food and Drug Administration and the Centers for Disease Control, but CEO Albert Bourla said earlier this week he believes a fourth dose is necessary. "The protection that you are getting from the third [dose], it is good enough, actually quite good for hospitalizations and deaths," he told CBS's Face the Nation. "It's not that good against infections, but doesn't last very long. But we are just submitting those data to the FDA and then we will see what the experts also will say outside Pfizer."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Pfizer has rolled out COVID-19 vaccines and boosters with varying regimens for specific age groups. Most recently, it postponed its request for approval for a shot for kids under age 5, saying it wants to compare data between a two-dose and three-dose regimen.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Summer Meza has worked at The Week since 2018, serving as a staff writer, a news writer and currently the deputy editor. As a proud news generalist, she edits everything from political punditry and science news to personal finance advice and film reviews. Summer has previously written for Newsweek and the Seattle Post-Intelligencer, covering national politics, transportation and the cannabis industry.
-
The nuclear threat: is Vladimir Putin bluffing?
Talking Point Kremlin's newest ballistic missile has some worried for Nato nations
By The Week UK Published
-
Layla: Amrou Al-Kadhi's queer love story splits critics
Talking Point Bilal Hasna gives a 'winning performance' in starring role – but the romance feels 'bland'
By The Week UK Published
-
Captain Tom: a tarnished legacy
Talking Point Misuse of foundation funds threatens to make the Moore family a disgrace
By The Week UK Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published